Challenges in Diagnosis and Therapeutic Strategies in Late-Onset Multiple Sclerosis.

J Pers Med · 2024 · PMC11051411 · PMID 38673027

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a notable trendno p-value reported

Data on ocrelizumab on reducing the relapse rate and the disability progression are controversial in two clinical trials, OPERA and ORATORIO, with a notable trend to benefit younger subjects [ 80 , 81 ].

also in 1,958 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.